HK Stock Market Move | AIM VACCINE (06660) rose nearly 8% in mid-day trading, planning to apply for A-share listing on the North Exchange. The "H+A" strategy is expected to drive valuation increases.

AIM VACCINE (06660) rose nearly 8% during the trading session, rising 6.78% at the time of publication to 3.15 Hong Kong dollars, with a turnover of 2.3795 million Hong Kong dollars. On the news front, recently, AIM VACCINE announced that the company had approved a resolution on March 30 to increase the issuance of domestic shares by no more than 40,000,000 shares, representing approximately 3.2611% of the total number of shares issued by the company before this issuance, and approximately 3.1582% of the total number of shares issued by the company after this issuance. In addition, the company plans to apply for an A-share listing on the Beijing Stock Exchange. According to the relevant regulations of the Beijing Stock Exchange for A-share listings, the company's domestic shares will need to be listed on the National Equities Exchange and Quotations system. It is reported that if AIM's progress is successfully completed, it could become the first company to return to the Beijing Stock Exchange from the Hong Kong Stock Exchange, paving the way for Hong Kong biopharmaceutical companies to list on the Beijing Stock Exchange. According to related data, CanSino Biologics Inc., also a vaccine company, has a valuation premium of up to 3.1 times higher for its A-shares compared to its H-shares. If AIM VACCINE achieves its 'H+A' strategic layout, it will not only enhance the company's valuation on the Hong Kong Stock Exchange and market activity, but also rapidly develop its brand value and business.